<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04126876</url>
  </required_header>
  <id_info>
    <org_study_id>2018/418</org_study_id>
    <nct_id>NCT04126876</nct_id>
  </id_info>
  <brief_title>A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma</brief_title>
  <acronym>INTRIM</acronym>
  <official_title>A Randomized Controlled Phase II Clinical Trial With Intradermal IMO-2125 (Tilsotolimod) in pT3-4 cN0M0 Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>A.J.M. van den Eertwegh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Idera Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, there is no widely used adjuvant treatment available to improve survival after
      surgical excision of a primary melanoma. In a previous study, loco-regional and systemic
      immune stimulations, as well as favourable clinical outcomes in terms of sentinel lymph node
      (SLN) tumor status and recurrence-free survival (RFS) in patients with clinical stage I-II
      melanoma who received a low dose of toll-like receptor 9 (TLR-9) CPG7909 (CpG-B ODN)
      intradermally at the excision site of the primary tumor prior to SLN biopsy (SNB) were
      described. In this phase II trial the investigators had investigated the clinical activity of
      a next-generation CpG-ODN, IMO-2125, and it's ability to induce loco-regional and systemic
      immune stimulation in pT3-4 cN0M0 melanoma patients who are scheduled to undergo a combined
      re-excision and SNB is
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2031</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A Randomized Controlled Phase II Multicenter Clinical Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Persons that are masked/ blinded for which medication the patient receives: participant, treating physician/ team (including the person giving the intradermal injection) and peron who collects the data.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of tumor positive sentinal lymph node (SLN)</measure>
    <time_frame>Seven days after the intradermal injection of Tilsotolimod (IMO-2125)</time_frame>
    <description>The rate of tumor positive sentinal lymph node (SLN)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune response in the SLN and peripheral blood</measure>
    <time_frame>Seven days after the intradermal injection of Tilsotolimod (IMO-2125)</time_frame>
    <description>Frequency and activation state of lymph node resident (LNR) conventional dendritic cells (DC) and melanoma antigen-specific T cell responses in the SLN and peripheral blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence free survival (RFS)</measure>
    <time_frame>At 5 years and 10 years after sentinel node biopsy (SNB)</time_frame>
    <description>The length of time from intradermal injection of Tilsotolimod (IMO-2125) to first documentation of recurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>At 5 years and 10 years after sentinel node biopsy (SNB)</time_frame>
    <description>The length of time from intradermal injection of Tilsotolimod (IMO-2125) to death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">214</enrollment>
  <condition>Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>Tilsotolimod (IMO-2125)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intradermal, single injection of 1 ml (8 mg) Tilsotolimod (IMO-2125) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intradermal, single injection of 1 ml plain saline (0.9% sodium chloride) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tilsotolimod</intervention_name>
    <description>Intradermal, single injection of 1 ml (8 mg) Tilsotolimod (IMO-2125) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).</description>
    <arm_group_label>Tilsotolimod (IMO-2125)</arm_group_label>
    <other_name>IMO-2125</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline (0.9% sodium chloride)</intervention_name>
    <description>Intradermal, single injection of 1 ml plain saline (0.9% sodium chloride) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older

          -  Histologically confirmed primary malignant melanoma cutis with a Breslow tumor depth
             &gt;2.0 mm

          -  Scheduled to undergo a combines re-excision and sentinel node biopsy (SNB)

          -  World Health Organization (WHO) Performance Status â‰¤1

          -  Agreement to use effective contraceptive methods from screening until at least 90 days
             after the IMO-2125 administration

          -  Written informed consent

        Exclusion Criteria:

          -  Known hypersensitivity to any oligodeoxynucleotide

          -  Active auto-immune disease requiring disease-modifying therapy at the tumr of
             screening

          -  Pathologically confirmed loco-regional or distant metastasis

          -  Non-skin melanoma

          -  Patients with another primary malignancy (some exceptions)

          -  Active systemic infections requiring antibiotics

          -  Women who are pregnant or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanja de Gruijl</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alfons JM van den Eertwegh</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica CL Notohardjo, MD</last_name>
    <phone>+3120 4444881</phone>
    <email>intrim@vumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>VU Medical Centere</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Koster BD, van den Hout MFCM, Sluijter BJR, Molenkamp BG, Vuylsteke RJCLM, Baars A, van Leeuwen PAM, Scheper RJ, Petrousjka van den Tol M, van den Eertwegh AJM, de Gruijl TD. Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I-II Melanoma: Data from Two Randomized Phase II Trials. Clin Cancer Res. 2017 Oct 1;23(19):5679-5686. doi: 10.1158/1078-0432.CCR-17-0944.</citation>
    <PMID>28972083</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 10, 2019</study_first_submitted>
  <study_first_submitted_qc>October 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2019</study_first_posted>
  <last_update_submitted>February 6, 2020</last_update_submitted>
  <last_update_submitted_qc>February 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>A.J.M. van den Eertwegh</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

